Breast Cancer Research and Treatment **70:** 221–222, 2001.

Author index, Volume 70

Abe, Y., 65
Absetz, P., 145
Agresti, R., 155
Ahn, S.H., 205
Airoldi, M., 185
Allison, J., 157
Allison, J., 227
Allison, J., 75
Aro, A.R, 145
Arveux, P., 137
Azorsa, D.O., 89
Bae, B.-N., 205
Beery, E., 27
Beex, L.V.A.M., 81
Beitel, L.K., 109
Benz, C.C., 213
Berkel, H.J., 117
Biganzoli, L., 55
Bonadonna, G., 163
Bonnefoi, H., 55
Brambilla, C., 163
Bult, P., 81
Bumma, C., 185
Cattel, L., 185
Chambers, A.F., 197
Coban, T., 47
Colonna, M., 137
Contu, A., 1
Conzen, S., 213
Cufer, T., 55
Cunliffe, H.E., 89
Demicheli, R., 163
Denison, U., 131
Dorn, R.V., 213
Dragowska, W.H., 11
Duronio, V., 11
Elhaji, Y.A., 109
Faber, L.E., 21
Fenig, E., 27
Fleming, G.F., 213
Foulkes, W.D., 109
Frank, W., 131
Ghirelli, C., 155
Gianni, L., 163
Gondo, H., 103
Gottlieb, B., 109
Grant, K., 213
Greene, G., 213
Grosclaude, P., 137
Haijima, H., 103
Hamilton, A., 55
Han, S., 205
Hedelin, G., 137
Hellman, S., 213
Henderson, C., 213
Hilakivi-Clarke, L., 213
Hoover, R., 213
Hota, C., 197
Hryniuk, W., 213
Hu, Y., 11
Iscan, M., 47
Jeffrey, S., 213
Kakudo, K., 39
Kameoka, S., 65
Kanfi, Y., 27
Kapucuoğlu, N., 47
Kato, I., 117
Kato, T., 65
Kawanishi, H., 103
Kerschbaum, F., 131
Kim, H.-J., 205
Kim, H.-Y., 205
Kim, K.H., 205
Kim, Y.-D., 205
Kimura, T., 65
Klaavuniemi, T., 47
Knott, K.K., 171
Kobayashi, M., 65
Koning, H.J. de, 145
Kute, T.E., 123
Li, B.D.L., 117
Lilling, G., 27
Lippman, M., 213
Livnat, T., 27
Lubet, R.A., 171
Lumbroso, R., 109
Lung, J., 213
Lesec'h, J.M., 137
Marchianó , A., 163
Marchionatti, S., 185
Mariani, G., 163
Mauriac, L., 55
Mayer, L., 11
Mayfield, S., 123
McGinley, J.N., 171
Medl, M., 131
Meltzer, P.S., 89
Ménard, S., 155
Mitchell, M., 213
Morelli, D., 155
Mori, I., 39
Moslinger-Gehmayr, R., 1
Nakagawa, H., 103
Nakamura, M., 39
Nakamura, Y., 39
Nishikawa, T., 65
Nordenberg, J., 27
Pang, H., 21
Park, K., 205
Pedani, F., 185
Pelkonen, O., 47
Peters-Engl, C., 131
Pezzella, G., 1
Piccart, M., 55
Pike, M., 213
Pinsky, L., 109
Raunio, H., 47
Raverdy, N., 137
Recalenda, V., 185
Ruers, T.J., 81
Sakurai, T., 39
Sauvage-Machelard, M., 137
Schaefer, P., 55
Schreck, M., 145
Sevelda, P., 131
Shan, L., 39
Shi, R., 117
Shoji, T., 103
Smith, M., 117
Soga, N., 65
Steele, V.E., 171
Suzuma, T., 39

Tagini, V., 185
Tagliabue, E., 155
Tagliabue, P., 163
Tamaki, T., 39
Tanaka, K., 103
Tjan-Heijnen, V.C.G., 81
Tretarre, B., 137
Trifiro, M.A., 109
Tuck, A.B., 197
Umemura, T., 39
Valagussa, P., 163
Vaughn, J.P., 123
Villa, E., 163
Wallis, A., 11
Wang, Q., 27
Wasserman, L., 27
Widt-Levert, L.M. de, 81
Wieder, R., 27
Yahalom, J., 27
Yamamoto, D., 103
Yang, Q., 39
Yoshimura, G., 39
Yu, H., 117
Zucchinelli, P., 163

Breast Cancer Research and Treatment **70:** 223–225, 2001.
© 2001 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 70

AIB1
  association with estrogen receptor-α 89-101
amitriptyline
  as a treatment for depression 1-10
  compared with paroxetine 1-10
androgen receptor gene
  polymorphic CAG repeat 109-116
angiogenesis
  as a predictor of long-term survival 65-74
apoptosis
  effect of Herceptin 123-129
  function of Bcl-2 proteins 11-20
axillary lymph nodes
  micro-metastases 81-88

basic fibroblast growth factor
  role of TGF-β 27-37
Bcl-2
  and Mcl-1 in MCF-7 human breast cancer 11-20
  role of cytotoxicity 11-20
bFGF
  role of TGF-β 27-37

CAG repeats
  of the androgen receptor gene 103-108
CA repeats
  in the *IGF-1* gene 117-122
cell cycle
  effect of Herceptin 123-129
cell invasion
  OPN-induced increase 197-204
chemotherapy
  as a treatment for patients with metastatic breast cancer 185-195
  p16INK4a protein expression 205-212
chromosome 3p24
  correlation with tumor progression 39-45
  role of RARβ2 39-45
classification
  dilemma 81-88
  of micro-metastases 81-88
  to prevent stage migration 81-88
cytochrome P450
  expression in breast tumors 47-54

depression
  treatment with paroxetine 1-10
docetaxel
  as a treatment for patients with metastatic breast cancer 185-195
  in combination with epirubicin 185-195
ductograms
  fiberoptic ductoscopy 103-108
  utility for patients with nipple discharge 103-108
ductography
  and fiberoptic ductoscopy 103-108
  for patients with nipple discharge 103-108

estrogen
  dependent breast cancer 21-26
  rapamycin effects 21-26
estrogen receptor-α
  associated with AIB1 89-101
  effect of vorozole 171-183
epidemiologic study
  examining survival rate among French women 137-143
epirubicin
  as a treatment for patients with LA/I or LO breast cancer 55-63
  as a treatment for patients with metastatic breast cancer 185-195
  in combination with docetaxel 185-195

fiberoptic ductoscopy
  ductograms 103-108
  utility for patients with nipple discharge 103-108
French patients
  survival rate 137-143

gemcitabine
  as a treatment for patients with metastatic breast cancer 163-169
  in combination with vinorelbine 163-169

Herceptin
  effect on breast cancer cells 123-129

HER-2
  binding by Herceptin 123-129
hormone dependence
  effect of vorozole 171-183

IGF-1
  polymorphic CA repeats 117-122
IGFBP-3
  polymorphic CA repeats 117-122
image analysis
  vorozole and ovarian hormone receptor status 171-183
immunohistochemistry
  p16INK4a protein expression 205-212
  vorozole and ovarian hormone receptor status 171-183
infusional 5-fluorouracil
  as a treatment for patients with LA/I or LO breast cancer 55-63
inhibitors
  of signal transduction pathway kinases 11-20
isolated tumor cells
  prognostic relevance 81-88

Japanese patients
  long-term survival 65-74

long-term survival
  among Japanese patients 65-74
  predicted by angiogenesis 65-74
loss of heterozygosity
  correlation with tumor progression 39-45
  RARβ2 39-45
lunar phases
  correlation with survival rate 131-135

mammary epithelial cells
  OPN-induced increase 197-204
mammography screening
  distinct groups of non-attenders 145-153
MCF-7 human breast cancer
  down-regulation of Bcl-2 11-20
  role of cytotoxicity 11-20
Mcl-1
  and Bcl-2 in MCF-7 human breast cancer 11-20
metastatic breast cancer
  treatment with gemcitabine and vinorelbine 163-169
  treatment with docetaxel and epirubicin 185-195
micro-metastases
  in axillary lymph nodes 81-88
  prognostic impact 81-88
microvessel density
  as a prognostic indicator for breast cancer 65-74
  assessing angiogenesis 65-74
mRNA
  CYP expression 47-54

neoadjuvant chemotherapy
  of breast cancer cells with CEF-infu 55-63
non-attenders
  attitudinal barriers 145-153
  knowledge gaps 145-153
  in mammography screening 145-153
normal breast tissue
  CYP mRNA levels 47-54

1-methyl-1-nitrosourea
  inducing rat mammary carcinomas 171-183
  vorozole and ovarian hormone receptor status 171-183
OPN-induced invasion
  uPA dependency 185
osteopontin
  induced increase in mammary epithelial cell invasiveness 197-204
ovarian hormone receptor status
  effect of vorozole 171-183
ovariectomy
  effect of vorozole 171-183

paroxetine
  as a treatment for depression 1-10
  compared with amitriptyline 1-10
polymorphic CAG repeat
  of the androgen receptor gene 109-116
polymorphic CA repeats
  in breast cancer 117-122
  in the *IGF-1* gene 117-122
polymorphism
  of the androgen receptor gene 109-116
  of CA repeats in the *IGF-1* gene 117-122
population based registry
  in France 137-143
  survival rate 137-143
progesterone receptor
  effect of vorozole 171-183
progestin
  effect on hormone dependent breast cancer 21-26
  rapamycin effects 21-26
p16INK4a protein expression
  in breast carcinoma 205-212

p21/WAF1/Cip1
increased levels 27-37
role of bFGF 27-37

rapamycin effects
on cell cycle progression 21-26
on estrogen dependent breast cancer 21-26
rapid emergence model
vorozole and ovarian hormone receptor status 171-183
retinoic acid receptor β
chromosome 3p24 39-45
loss of heterozygosity 39-45
reverse transcriptase-polymerase chain reaction
screeening CYP mRNA levels 47-54

selective serotonin reuptake inhibitor
as a treatment for depression 1-10
sentinel lymph node
replacing ALMD 81-88
staging breast cancer 81-88
S-phase
induced by estradiol-17-β 21-26
SSRI
as a treatment for depression 1-10
stage at diagnosis
correlation with age and treatment 137-143
in France 137-143
survival
in France 137-143
in Japan 65-74
long-term 65-74
predicted by angiogenesis 65-74
relation with lunar phases 131-135
relation with p16INK4a protein expression 205-212

TCA
as a treatment for depression 1-10
T47D breast cancer cells
induced by estrogen 21-26
TGF-β
role in bFGF inhibition of MCF-7 cells 27-37
transcriptional coactivators
AIB1 89-101
transforming growth factor β
role in bFGF inhibition of MCF-7 cells 27-37
treatment
dilemma caused by introduction of SN biopsy 81-88
tricyclic antidepressant
as a treatment for depression 1-10

uPA dependency
of OPN-induced invasion 197-204
urokinase
OPN-induced invasion 197-204

vinorelbine
as a treatment for patients with metastatic breast cancer 163-169
in combination with gemcitabine 163-169
vorozole
and ovarian hormone receptor status 171-183